HighTower Advisors LLC Acquires 22,500 Shares of Biodesix, Inc. (NASDAQ:BDSX)

HighTower Advisors LLC grew its holdings in Biodesix, Inc. (NASDAQ:BDSX) by 17.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 153,934 shares of the company’s stock after acquiring an additional 22,500 shares during the quarter. HighTower Advisors LLC owned 0.11% of Biodesix worth $236,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BDSX. Barclays PLC increased its position in shares of Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares during the period. Stephens Inc. AR acquired a new position in shares of Biodesix in the 4th quarter worth approximately $303,000. Geode Capital Management LLC lifted its position in shares of Biodesix by 50.7% during the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after buying an additional 270,724 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Biodesix during the third quarter valued at $10,849,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Insider Buying and Selling at Biodesix

In other news, CEO Scott Hutton sold 83,660 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at $645,791.24. This represents a 10.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 128,702 shares of company stock valued at $118,406. 69.20% of the stock is currently owned by company insiders.

Biodesix Trading Up 3.6 %

BDSX opened at $0.63 on Thursday. The firm has a 50 day simple moving average of $0.87 and a 200 day simple moving average of $1.26. Biodesix, Inc. has a fifty-two week low of $0.59 and a fifty-two week high of $2.04. The company has a market cap of $91.63 million, a price-to-earnings ratio of -1.61 and a beta of 1.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The company had revenue of $20.43 million during the quarter, compared to analysts’ expectations of $19.92 million. On average, sell-side analysts anticipate that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, William Blair reiterated an “outperform” rating on shares of Biodesix in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $2.95.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.